-+ 0.00%
-+ 0.00%
-+ 0.00%

BiomX To Provide Latest Update On Phase 1b/2a Clinical Trial Data For BX004 At The North American Cystic Fibrosis Conference

Benzinga·09/18/2024 12:19:15
Listen to the news

BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections.

 

The findings will be presented in two sessions at the North American Cystic Fibrosis Conference in Boston. First, a poster titled "Safety and efficacy of nebulized phage in CF patients with chronic Pseudomonas aeruginosa pulmonary infection: A phase 1b/2a randomized, double-blind placebo-controlled, multicenter study" will be displayed with lead author present on Friday, September 27, 2024, 1:15-2:15 PM ET. The poster will be available on the Company's website following the end of the poster session. On Saturday, September 28, 2024, Urania Rappo, MD (Senior Director of Clinical Development at BiomX) will discuss the findings in Workshop 38 "Epidemiology & Management of Infection in CF" from 10:15 AM to 12:15 PM ET, Room 257AB.